Comparison of Dihydroartemisinin-Piperaquine versus Sulphadoxine-Pyrimethamine for malaria prevention in pregnancy
Not Applicable
Recruiting
- Conditions
- MalariaPregnancy and Childbirthmalaria prevention during pregnancy
- Registration Number
- PACTR201808204807776
- Lead Sponsor
- Federal Teaching Hospital Abakaliki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 360
Inclusion Criteria
1.Pregnant women between 14 weeks and 24 weeks gestation with viable pregnancy.
2.Women who have not received intermittent preventive treatment with sulphadoxine–pyrimethamine during the index pregnancy.
3.Women not allergic to sulphadoxine-pyrimethamine or dihydroartemisinin-piperaquine.
4.Women willing to deliver in the study hospital.
Exclusion Criteria
1.Women in the first trimester of pregnancy.
2.HIV positive pregnant women
3.Women allergic to sulphadoxine-pyrimethamine or dihydroartemisini-piperaquine.
4.Women with high-risk pregnancies e.g. medical diseases in pregnancy (sickle cell disease, diabetes mellitus, hypertensive disorders in pregnancy) and multiple gestations.
5.Women who do not consent to the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method